湖南發展(000722.SZ):擬使用5000萬元參與認購達晨創鴻基金份額
格隆匯6月30日丨湖南發展(000722.SZ)公佈,為進一步優化資產結構,提升公司資金投資收益水平和資本運作能力,推進公司大健康產業的發展,公司作為有限合夥人使用自有資金人民幣5000萬元參與認購深圳市達晨創鴻私募股權投資企業(有限合夥)(“達晨創鴻基金”)份額。
醫療健康為達晨創鴻基金重點投資領域之一,與公司拓展大健康產業具有協同性。此次投資有利於公司藉助專業投資機構的專業團隊、項目資源和平台優勢,把握戰略性投資先機,提升公司對外投資能力,提高投資效益,推進公司大健康產業的發展,符合公司戰略規劃及長遠利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.